Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s Radio-Enhancer NBTXR3 Is Being Tested In Multiple Indications

Executive Summary

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

You may also be interested in...



Nanobiotix's Hensify Earns CE Mark For Soft-Tissue Sarcoma

The CE mark will make Hensify nanoparticle radioenhancers available in 27 European countries. Hensify is the brand name for NBTXR3, an aqueous suspension of crystalline hafnium oxide nanoparticles, approved specifically for treating locally advanced soft-tissue sarcoma.

CytomX’s Probody T-Cell Platform Produces Astellas Pact

Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.  

Experts Say COVID-19 Battle Needs More Funding, Cooperation

Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141695

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel